NEW! Equitable Community Access to Pharmacist Services Act (ECAPS)

Introduced in the U.S. House of Representatives on March 24, 2022, the Equitable Community Access to Pharmacist Services Act, H.R. 7213, would authorize pharmacists to provide care and receive reimbursement for pandemic-related services for our nation’s seniors.

Learn more  

APhA’s Learning Library

We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.

Learn more  

Community Pharmacy Workplace Summit

APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.

Learn more  

Featured Education

Upcoming Events

Practice Resources

Tools and resources to support your practice

Access Now  


Latest from APhA

View CEO Blog

Workplace conditions and well-being

We hear you! Your pharmacy workplace is stressed and stretched. You have rapidly growing concerns for patient safety. Still, you are there—every day—to care for your patients despite conditions that seem to be working against you.


APhA–APPM, SIGs, and APhA-APRS Announce 2022 Election Results

WASHINGTON, D.C.—The American Pharmacists Association (APhA) announced the results of elections for the Academy of Pharmaceutical Research and Science (APhA–APRS), Academy of Pharmacy Practice and Management (APhA–APPM), and the APhA–APPM Special Interest Groups (SIGs) today.


Pharmacy news

View all news

ACIP updates adult recommendations for pneumococcal vaccines

CDC recently approved new pneumococcal vaccine (PCV) recommendations. Now, CDC recommends the use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65 years or older and for adults aged 19 to 64 years with certain underlying medical conditions or other risk factors who have not previously received a PCV vaccine or whose previous vaccination history is unknown.

PCSK9 inhibitors seem to benefit those with high cardiovascular risk

PCSK9 inhibitors appear to lower nonfatal myocardial infarction in adults with high or very high cardiovascular risk but not in those with low or moderate risk, according to a new study published in The BMJ.